The expansion of CAR T-cell therapies faces hurdles due to toxicity management challenges such as cytokine release syndrome and neurotoxicity. Experts stress the need for improved strategies to broaden patient access as new T cell-based therapies emerge from clinical trials. Advances in CRS and ICANS mitigation are critical for scaling these life-saving immunotherapies.